{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:13:33Z","timestamp":1795180413910,"version":"4.10.3"},"reference-count":168,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment of non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number of prior chemotherapy cycles, amount of bone marrow tumor involvement) determine the extent of CIT. CIT is related to the type and dose of chemotherapy, with regimens containing gemcitabine, platinum, or temozolomide producing it most commonly. Bleeding and the need for platelet transfusions in CIT are rather uncommon except in patients with platelet counts below 25x109\/L in whom bleeding rates increase significantly and platelet transfusions are the only treatment. Nonetheless, platelet counts below 70x109\/L present a challenge. In patients with such counts, it is important to exclude other causes of thrombocytopenia (medications, infection, thrombotic microangiopathy, post-transfusion purpura, coagulopathy and immune thrombocytopenia). If these are not present, the common approach is to reduce chemotherapy dose intensity or switch to other agents. Unfortunately decreasing relative dose intensity is associated with reduced tumor response and remission rates. Thrombopoietic growth factors (recombinant human thrombopoietin, pegylated human megakaryocyte growth and development factor, romiplostim, eltrombopag, avatrombopag and hetrombopag) improve pretreatment and nadir platelet counts, reduce the need for platelet transfusions, and enable chemotherapy dose intensity to be maintained. National Comprehensive Cancer Network guidelines permit their use but their widespread adoption awaits adequate phase III randomized, placebo-controlled studies demonstrating maintenance of relative dose intensity, reduction of platelet transfusions and bleeding, and possibly improved survival. Their potential appropriate use also depends on consensus by the oncology community as to what constitutes an appropriate pretreatment platelet count as well as identification of patient-related and treatment variables that might predict bleeding.<\/jats:p>","DOI":"10.3324\/haematol.2021.279512","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:09:32Z","timestamp":1654096172000},"page":"1243-1263","source":"Crossref","is-referenced-by-count":154,"title":["Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies"],"prefix":"10.3324","volume":"107","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"36027","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-46202-0.00007-8"},{"key":"36028","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640578"},{"key":"36029","unstructured":"Kuter D. Clinical applications of thrombopoietic growth factors."},{"key":"36030","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.013"},{"key":"36031","unstructured":"National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017."},{"key":"36032","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"36033","unstructured":"Slichter SJ. Optimizing platelet transfusions in chronically thrombocytopenic patients. Semin Hematol. 1998; 35(3):269-278."},{"key":"36034","unstructured":"Slichter SJ, LeBlanc R, Jones MK. Quantitative analysis of bleeding risk in cancer patients (PTS) prophylactically transfused at platelet (PLT) counts (CTS) of, 5,000, 10,000, or 20,000. Blood. 1999; 94(3):376a."},{"key":"36035","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(21)00047-3"},{"key":"36036","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.5.1105.1105"},{"key":"36037","unstructured":"Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A.. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica. 2003; 88(5):547-554."},{"key":"36038","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04771.x"},{"key":"36039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904084"},{"key":"36040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1137"},{"key":"36041","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012035.pub2"},{"key":"36042","unstructured":"Hassan BA, Yusoff ZB, Hassali MA, Bin Othman S. Treatment patterns and outcomes in management of solid cancer patients suffering from thrombocytopenia in Penang hospital. Asian Pac J Cancer Prev. 2011; 12(11):2841-2845."},{"key":"36043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197207272870401"},{"key":"36044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1377"},{"key":"36045","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2416-x"},{"key":"36046","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.03.001"},{"key":"36047","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04875-1"},{"key":"36048","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.02.003"},{"key":"36049","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0399-y"},{"key":"36050","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.12.019"},{"key":"36051","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.12.017"},{"key":"36052","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-131"},{"key":"36053","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251900"},{"key":"36054","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.660628"},{"key":"36055","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11934"},{"key":"36056","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903026492"},{"key":"36057","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10369"},{"key":"36058","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08707.x"},{"key":"36059","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001617"},{"key":"36060","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313905110"},{"key":"36061","doi-asserted-by":"publisher","DOI":"10.1038\/nm1760"},{"key":"36062","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17872"},{"key":"36063","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24759"},{"key":"36064","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065066"},{"key":"36065","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"36066","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-19.2.72"},{"key":"36067","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2008.00942.x"},{"key":"36068","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276691"},{"key":"36069","unstructured":"Gonzalez CE, Pengetze YM. Post-transfusion purpura. Curr Hematol Rep. 2005; 4(2):154-159."},{"key":"36070","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S189176"},{"key":"36071","unstructured":"Levi M.. Cancer and DIC. Haemostasis. 2001; 31(Suppl 1):47-8."},{"key":"36072","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-79962-9_9"},{"key":"36073","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013321"},{"key":"36074","unstructured":"Kuter DJ, Rosenberg RD. Disorders of hemostasis. 1991;577-598."},{"key":"36075","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20290"},{"key":"36076","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1687893"},{"key":"36077","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21276"},{"key":"36078","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.565"},{"key":"36079","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700747"},{"key":"36080","doi-asserted-by":"publisher","DOI":"10.2165\/11594310-000000000-00000"},{"key":"36081","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.020"},{"key":"36082","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13595"},{"key":"36083","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191206"},{"key":"36084","unstructured":"Wright JH. A rapid method for the differential staining of blood films and malarial parasites. J Medical Res. 1902; 7(1):138-144."},{"key":"36085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM190606071542301"},{"key":"36086","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12758"},{"key":"36087","doi-asserted-by":"publisher","DOI":"10.1038\/nature21706"},{"key":"36088","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-259663"},{"key":"36089","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110750"},{"key":"36090","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-307-3_5"},{"key":"36091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394858"},{"key":"36092","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4446.423k19_4446_4452"},{"key":"36093","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.1981.tb00513.x"},{"key":"36094","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.5.1036.bloodjournal6451036"},{"key":"36095","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318210e685"},{"key":"36096","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2093"},{"key":"36097","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)80186-6"},{"key":"36098","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"key":"36099","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402081"},{"key":"36100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0939"},{"key":"36101","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2000.00305.x"},{"key":"36102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2260.h81802002260_2260_2262"},{"key":"36103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712253372602"},{"key":"36104","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28253"},{"key":"36105","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21958"},{"key":"36106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733.pub2"},{"key":"36107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138920"},{"key":"36108","unstructured":"Tepler I, Elias L, Smith JW. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996; 87(9):3607-3614."},{"key":"36109","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7610"},{"key":"36110","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.2.651"},{"key":"36111","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(98)90057-9"},{"key":"36112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.803.803"},{"key":"36113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.795.003k25_795_801"},{"key":"36114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2720"},{"key":"36115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110352"},{"key":"36116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01359.x"},{"key":"36117","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0652-8"},{"key":"36118","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530140711"},{"key":"36119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4068.bloodjournal87104068"},{"key":"36120","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2028.x"},{"key":"36121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.6.3132"},{"key":"36122","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.139"},{"key":"36123","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1920.x"},{"key":"36124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2234"},{"key":"36125","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-405"},{"key":"36126","unstructured":"Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995; 55(16):3509-3512."},{"key":"36127","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12781"},{"key":"36128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.511.bloodjournal882511"},{"key":"36129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.10.3457"},{"key":"36130","unstructured":"Li J, Xia Y, Bertino A, Coburn J, Kuter DJ. Characterization of an anti-thrombopoietin antibody that developed in a cancer patient following the injection of PEG-rHuMGDF. Blood. 1999; 94:51a."},{"key":"36131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3241"},{"key":"36132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2599"},{"key":"36133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761262"},{"key":"36134","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05975.x"},{"key":"36135","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1841748"},{"key":"36136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2909.2909"},{"key":"36137","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0366"},{"key":"36138","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.09.006"},{"key":"36139","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.02.005"},{"key":"36140","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1382-0"},{"key":"36141","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-2296-9.00008-7"},{"key":"36142","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260"},{"key":"36143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002625"},{"key":"36144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-313908"},{"key":"36145","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01575-1"},{"key":"36146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073255"},{"key":"36147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534743"},{"key":"36148","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200931"},{"key":"36149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702063360603"},{"key":"36150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.15.2852"},{"key":"36151","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm341"},{"key":"36152","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00005"},{"key":"36153","unstructured":"Bai CM, Xu GX, Zhao YQ, Han SM, Shan YD. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004; 26(4):437-441."},{"key":"36154","unstructured":"Bai CM, Zou XY, Zhao YQ, Han SM, Shan YD. Thrombopoietin Clinical Trial Cooperation Group. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia]. Zhonghua Yi Xue Za Zhi. 2004; 84(5):397-400."},{"key":"36155","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1459605"},{"key":"36156","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/141134"},{"key":"36157","unstructured":"Abudurousuli R, Luo T, Liu R. Research on the recombinant human thrombopoietin in the treatment of thrombocytopenia caused by tumor chemotherapy: a meta-analysis. In J Intell Syst. 2121; 3:184-192."},{"key":"36158","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2074-2"},{"key":"36159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01931"},{"key":"36160","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.180166"},{"key":"36161","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.510051"},{"key":"36162","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.326"},{"key":"36163","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2319-9"},{"key":"36164","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701539"},{"key":"36165","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"36166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"36167","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1134::AID-CNCR17>3.0.CO;2-9"},{"key":"36168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.01.011"},{"key":"36169","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.093872"},{"key":"36170","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3332"},{"key":"36171","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01101-4"},{"key":"36172","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1822-1"},{"key":"36173","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2008.40.1.22"},{"key":"36174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9007"},{"key":"36175","doi-asserted-by":"publisher","DOI":"10.1159\/000320640"},{"key":"36176","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.015"},{"key":"36177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"36178","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2012.13.5.1837"},{"key":"36179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"36180","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9114"},{"key":"36181","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"36182","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0360-x"},{"key":"36183","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9217-1"},{"key":"36184","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.2976"},{"key":"36185","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9220"},{"key":"36186","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.10.004"},{"key":"36187","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"36188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2071"},{"key":"36189","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5902"},{"key":"36190","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70178-0"},{"key":"36191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"36192","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"36193","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.11.6585"},{"key":"36194","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015; 29(4):282-294."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279512\/74473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279512\/74519","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10653\/74473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:49Z","timestamp":1794045709000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":168,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279512","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}